Articles

This review article provides a comprehensive anatomical analysis of soccer footwear, delving into the intricate structure and functional roles of its constituent components, including the upper, heel counter, tongue, toe box, outsole/sole plate, studs, and insole. Manufacturing processes influencing these structural elements are also discussed. Current market offerings and patented innovations in soccer cleat technology are examined through a biomechanical lens, highlighting their intended functions and limitations. A critical synthesis of existing knowledge underscores the anatomical and biomechanical distinctions between male and female athletes' feet, arguing for the necessity of sex-specific footwear design. This review culminates in emphasizing the imperative for specifically engineered soccer footwear for female athletes to optimize performance, enhance comfort, and mitigate the elevated risk of lower extremity injuries prevalent in the female game, thereby identifying crucial directions for future research in sports biomechanics and footwear engineering.

This systematic review aimed to evaluate the biomechanical properties, functional performance, and clinical outcomes of different hip prosthesis materials and designs used in total hip arthroplasty (THA). A comprehensive search strategy identified 34 peer-reviewed studies published between 2015 and 2024. The materials investigated included cobalt-chromium-molybdenum (CoCrMo), titanium alloys, PEEK, ceramics, and advanced surface coatings such as polycrystalline diamond (PCD). In addition, dual mobility systems, lattice structures, and additively manufactured and patient-specific implants were assessed. The studies utilized clinical trials, finite element analysis, and biomechanical testing to compare outcomes such as wear resistance, stress distribution, osseointegration, and range of motion. The findings demonstrated that titanium alloys and porous lattice structures reduce stress shielding, while ceramics and CoCrMo provide superior wear resistance. Dual mobility implants improved joint stability and range of motion, particularly in high-risk patients. PEEK and PCD showed promising properties but lacked robust long-term data. The integration of advanced manufacturing technologies and material innovations has led to more personalized and biomechanically efficient solutions for THA. Further longitudinal studies are needed to validate these developments. This review provides a critical synthesis of the biomechanical, functional, and clinical implications of contemporary hip prosthetic systems.

The pharmaceutical industry is undergoing a profound transformation driven by advancements in Information Technology (IT), with Enterprise Resource Planning (ERP) systems playing a pivotal role in reshaping operations. These systems offer integrated solutions that streamline key business processes, such as production, inventory management, supply chain optimization, regulatory compliance, and data integration, contributing significantly to operational efficiency and organizational agility. This paper explores the evolution and impact of ERP systems within the pharmaceutical sector, highlighting their contributions to overcoming the industry’s inherent challenges, including complex regulatory requirements, the need for accurate and real-time data, and the demand for supply chain resilience. The integration of cloud-based ERP solutions, the incorporation of emerging technologies like Artificial Intelligence (AI), Machine Learning (ML), and the Internet of Things (IoT), and enhanced data analytics capabilities have revolutionized pharmaceutical IT. These advancements not only reduce operational costs, improve forecasting accuracy, and enhance collaboration but also ensure compliance with stringent global regulations, such as Good Manufacturing Practices (GMP) and FDA guidelines. Moreover, ERP systems have been instrumental in managing the pharmaceutical supply chain, ensuring product traceability, and improving inventory control and order fulfillment processes. This manuscript examines how ERP systems enable pharmaceutical companies to maintain high standards of product quality, improve decision-making, and ensure the safety and efficacy of drugs through robust tracking and auditing mechanisms. A case study of a pharmaceutical company that implemented an ERP system demonstrates the tangible benefits, including increased operational efficiency, improved compliance rates, and enhanced customer satisfaction. However, despite the clear advantages, challenges such as customization complexities, data integration issues, and resistance to change remain. As the pharmaceutical industry continues to evolve, ERP systems will remain a cornerstone of digital transformation, facilitating smarter decision-making, better resource management, and enhanced collaboration across global operations. This paper also identifies future trends, including the potential of AI and blockchain technologies in further strengthening ERP systems and transforming the pharmaceutical landscape.

Drug shortages represent a significant and growing challenge within the pharmaceutical supply chain, with profound implications for patient care, public health, and healthcare costs. This manuscript provides a comprehensive examination of the causes and impacts of drug shortages, highlighting the multifaceted nature of this issue. Key factors contributing to shortages include manufacturing complications, limited availability of active pharmaceutical ingredients (APIs), market dynamics that discourage the production of less profitable medications, and regulatory challenges that slow down the approval process for new manufacturing capacities. The consequences of these shortages are far-reaching. Patients often face treatment delays, which can lead to adverse health outcomes, increased hospitalization rates, and even mortality. Healthcare providers experience heightened operational costs as they seek alternative therapies and manage complications resulting from inadequate treatment. Furthermore, the frequent occurrence of drug shortages erodes public trust in both the healthcare system and the pharmaceutical industry, leading to decreased patient adherence to prescribed therapies. To mitigate the impacts of drug shortages, this manuscript proposes several strategic solutions, including enhanced communication among stakeholders, diversification of supply sources, increased regulatory flexibility, and collaborative approaches between public and private sectors. Additionally, raising awareness among healthcare providers and patients regarding the causes and potential alternatives can empower stakeholders to navigate shortages effectively. Ultimately, addressing drug shortages necessitates a proactive and coordinated effort from all participants in the pharmaceutical supply chain. By implementing these strategies, stakeholders can enhance the resilience of the supply chain, ensuring that essential medications remain accessible and that patient care is not compromised. The findings of this manuscript underscore the urgent need for ongoing vigilance and collaborative action to tackle the challenges posed by drug shortages, safeguarding public health and improving healthcare outcomes globally.

Active Pharmaceutical Ingredients (APIs) serve as the cornerstone of pharmaceutical development, driving therapeutic efficacy and safety in drug formulations. This article provides a comprehensive overview of the lifecycle of APIs, starting from their discovery and development, through to manufacturing processes and regulatory oversight. The development of APIs begins with intensive research and discovery efforts, where medicinal chemists and pharmacologists identify and optimize potential compounds through computational modelling, high-throughput screening, and structure-activity relationship studies. Promising candidates undergo rigorous preclinical testing to assess pharmacological properties, safety profiles, and potential adverse effects in animal models. Upon successful preclinical outcomes, APIs progress to clinical trials, involving phases of testing in human subjects to evaluate efficacy, dosage regimens, and safety profiles under controlled conditions. Clinical trial data are meticulously analyzed to support regulatory submissions, demonstrating the API's therapeutic benefits and safety for eventual patient use. Manufacturing APIs involves complex chemical synthesis or biotechnological methods, ensuring precise control over reaction conditions, purity, and yield. The scale-up from laboratory synthesis to industrial production demands adherence to Good Manufacturing Practices (GMP), where stringent quality control measures verify consistency, potency, and stability throughout production batches. Regulatory oversight by authorities such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe ensures that APIs meet stringent standards of safety, efficacy, and quality before market approval. Manufacturers must submit comprehensive Chemistry, Manufacturing, and Controls (CMC) data, detailing manufacturing processes, analytical methods, and stability studies to support regulatory filings.

Consumer behavior is evolving, demanding a wide range of products with fast shipping and reliable service. The automotive aftermarket industry, worth billions, requires efficient distribution systems to stay competitive. Manufacturers strive to balance growth with product and service excellence. Distributors and retailers face the challenge of maintaining competitive pricing while keeping inventory levels low. An adequate supply chain and accurate product data are crucial for product availability and reducing stock issues. This ultimately increases profits and customer satisfaction.

Active Pharmaceutical Ingredients (APIs) form the backbone of pharmaceutical formulations, influencing their efficacy, safety, and stability. Essence control of APIs involves stringent regulation and optimization of their chemical, physical, and biological properties to ensure consistent quality and therapeutic outcomes. This manuscript explores the critical aspects of essence control in APIs, including synthesis, characterization, quality assessment, and regulatory considerations. The synthesis of Active Pharmaceutical Ingredients is a pivotal stage in pharmaceutical manufacturing, where precise control over chemical reactions and process conditions is paramount to achieving high-quality, safe, and effective medicines. Advances in synthetic methodologies, optimization strategies, sustainability practices, and the implementation of PAT technologies continue to drive innovation in API synthesis, supporting the development of novel therapeutic agents and enhancing pharmaceutical manufacturing efficiency.

The extensive globalization of services and rapid technological advancements driven by IT have heightened the competitiveness of organizations in introducing innovative products and services. Among the noteworthy innovations is enterprise resource planning (ERP). An integral field in computer science, known as artificial intelligence (AI), is undergoing a transformative integration into various industries. Grasping the concept of artificial intelligence and its application in diverse business applications is crucial, given its broad and intricate nature. The primary focus of this paper is to delve into the realm of artificial intelligence and its utilization within enterprise resource planning. The study not only explores artificial intelligence but also delves into related concepts such as machine learning, deep learning, and neural networks in greater detail. Drawing upon existing literature, this research examines various books and online resources discussing the intersection of artificial intelligence and ERP. The findings reveal that the impact of AI is evident as businesses attain heightened levels of analytical efficiency across different ERP domains, thanks to remarkable advancements in AI, machine learning, and deep learning. Artificial intelligence is extensively employed in numerous ERP areas, with a particular emphasis on customer support, predictive analysis, operational planning, and sales projections.

This charge-ahead paper suggests that transitioning the automotive industry towards a zero-carbon ecosystem from material to end-of-life can be accomplished through disruptive zero-carbon manufacturing in the broad area of all-electric vehicle production technology. To accomplish zero carbon emission automotive manufacturing in the vehicle assembly domain, future paradigms must converge on the decoupling of carbon dioxide emissions from automobile manufacturing and use the design, processing, and manufacturing conditions. The envisioned zero carbon emission vehicle manufacturing domain consists of two complementary components: (a) making more efficient use of energy and (b) reducing carbon in energy use. This paper presents the status of key scientific and technological advancements to bring the manufacturing model of today to a zero-carbon ecosystem for the entire automotive industry of tomorrow. This paper suggests the groundbreaking application of dynamic and distributed predictive scheduling algorithms and open sensing and visualization technology to meet the zero carbon emission vehicle manufacturing goals. Power-aware high-performance computing clusters have recently become a viable solution for sustainable production. Advances in scalable and self-adaptive monitoring, predictive analytics, timeline-based machine learning, and digital replica of cyber-physical systems are also seen co-evolving in the zero carbon manufacturing future. These methods are inspired by initiatives to decouple gross domestic product growth and energy-related carbon dioxide emissions. Stakeholders could co-design and implement shared roadmaps to transition the automotive manufacturing sector with relevant societal and environmental benefits. The automated mobility sector offers a program, an industry-leading example of transforming an automotive production facility to carbon neutrality status. The conclusions from this paper challenge automotive manufacturers to engage in industry offsetting and carbon tax programs to drive continuous improvement and circular vehicle flows via a multi-directional zero-carbon smart grid.

Failure prediction can be achieved through prognostics, which provides timely warnings before failure. Failure prediction is crucial in an effective prognostic system, allowing preventive maintenance actions to avoid downtime. The prognostics problem involves estimating the remaining useful life (RUL) of a system or component at any given time. The RUL is defined as the time from the current time to the time of failure. The goal is to make accurate predictions close to the failure time to provide early warnings. J S Grewal and J. Grewal provide a comprehensive definition of RUL in their paper "The Kalman Filter approach to RUL estimation." A process is a quadruple (XU f P), where X is the state space, U is the control space, P is the set of possible paths, and f represents the transition between states. The process involves applying control values to change the system's state over time.

The complexity of manufacturing photolithography has increased significantly. The increase in the level of integration has driven smaller feature-sized integrated circuits (ICs). The evolution in stepper technologies has been geometric. This has enabled the printing of printed ICs with a 45 nm feature size. Improvement in lithographic technology is moving towards 32 nm. This feature-size roadmap poses many challenges to semiconductor manufacturing technology. Advanced photomask synthesis, high-NA steppers, and computational lithography are some examples of the solution space. Optical proximity correction (OPC) and model-based optical proximity correction (MBOPC) are subsets of this solution space. OPC has matured significantly and is the de facto solution for manufacturing photomasks up to the 65 nm node. The OPC technique has been further refined as model-based OPC and has been applied to advanced printing technology of 45 nm. The OPC solution for 45 nm technology has limitations of mask rule check (MRC) and manufacturability restrictions. These restrictions are inevitable in OPC and MBOPC solutions because of the limits in lithographic technology. The technology evolution towards 32 nm has equally challenged the non-linear treatment of wafer-level problems in OPC solutions. PBOPC has limitations in reducing the wafer optical proximity error of the granny's issue, edge placement, mask rule check, etc. PBOPC also has limitations in reducing the mask error enhancement factor. With all these challenges, it is still a formidable solution methodology to address the wafer and mask level issues. Such a formidable solution architecture can result in a limited number of PBOPC solutions. This text looks at the performance of advanced PBOPC features on exposure tuning and the effects of higher-order wafer and aerial image effects. This text also discusses the performance of continuous process correction of masks, lenses, and scanners.

The advancement of modern manufacturing is synonymous with the growth of automation. Automation replaces human operators, improves productivity and quality, and reduces costs. However, the initial financial cost and knowledge requirements can be barriers to embracing automation. Manufacturers are now seeking smart manufacturing, known as the fourth industrial revolution. Smart manufacturing goes beyond automation and utilizes IoT, AI, and big data for optimized production. In a smart factory, production can be linked and controlled innovatively, leading to increased performance, agility, and reduced costs.

The manufacturing industry has embraced modern technologies such as big data, machine learning, and artificial intelligence. This paper examines AI and machine learning developments in the manufacturing industry, comparing current practices and data-driven projects. It aims better to understand these technologies and their potential benefits and challenges. The research identifies opportunities for innovative business solutions and explores industry practices and research results. The paper focuses on implementation rather than technical aspects, aiming to enhance knowledge in this area.

This paper includes the impacts of the Internet of Things (IoT), Big Data, and other emerging technologies in the vehicle production sector, digital connectivity, and sustainable transport system. Automated and intelligent transportation for safe, efficient, and sustainable transport systems will be stressed. Key factors to promote automated or connected vehicles including connected environment, integration of all transport modes, advanced cooperative systems, and policy enforcement will be discussed. This paper contains the Axiomatic Categorisation Framework (AFS) for the dynamic alignment in a collection of disparate functions in cyber-physical systems (CPS). Developed system is enhanced for breaking the rules within autonomous vehicles (AV). It means the human personal injury is inevitable while the vehicle does not do any rules. Especially in complicated traffic situations, many of the constraints are mutually exclusive, and there is no way to obey all of them at a time. Also, there is no way to ensure that the self-driving vehicle has priority in all situations [1]. Public distrust in AV systems has to be increased and the investment in this technology has to slow down. Instead, a human driver should be partially responsible for operation. The development of a driver-behavior assistant (DBA) system is proposed, which should be able to break the rules for the distances of such slow development. It is intended to be effective in non-deterministic situations while maintaining the safety of the AV and those involved in the event. A driver's actions would not only be acceptable as a driving strategy but also would be predictable, and therefore other road users could unambiguously react.

Factory owners and vehicle manufacturers increasingly opt for predictive analytics to inform their decisions. While predictive analytics have been proven to provide insights into the initiation of maintenance measures before a machine actually fails, the right models and features could have a significant impact on the budget spent and resources allocated. This means that financially oriented questions need to at least partially guide the decisions in the planning phase of data science projects. Data-driven approaches will play an increasingly important role, but only a few of the firms that were confident performed logistic regression models for predictive maintenance. Also, from the available knowledge, data-driven classification models connecting vehicle component failures and the occurrence of delays at the assembly line have not been published. This paper utilizes a real-world data-driven approach using classification models in predictive analytics by vehicle manufacturers and thereby links the financial implications of such data science projects to their results. We expand the existing literature on predictive maintenance and possess a unique dataset of newly launched series of vehicles, presented as-is. Our research context is of interest to researchers and practitioners in the automotive industry that manage and plan the final vehicle assembly with just-in-time principles, factoring the consequences of component failures on the assembly process. Key findings of this paper highlight that while minor tweaking of the models is possible, their potential input in decision-making processes for budget optimization is limited.

The supply chain ecosystem plays a very important role in the success or failure of organizations, markets, and economies. Supply chain ecosystems are broadly defined as supply chain organizations and their collaborators. Today's combined challenges of pandemic shutdowns, rising internet usage, and skyrocketing climate change concerns demand that the supply chain ecosystem better connect with customers, when and how they want, to provide products and services with high levels of availability and zero defects, yet collaboratively do this to reduce transportation and production risks, often at the same time reducing operational costs and carbon footprints. Addressing these challenges, this work explores the cloud delivery capabilities of cloud-native architectures to enable the big data integrations and analytics that are needed to grow smarter supply chain ecosystems. This work describes what smart supply chain ecosystems are and how they are planning to grow their technology and integration capabilities. Discussing the industry-leading advanced and manufacturing technology producer ecosystems, it is explained how their technology collaboration and investment plans are driven by climate change and job creation goals. With these background models, the work examines the new digital reality of customer-driven experiences and economies that are demanding cloud-native and intelligent technology partnerships to deliver climate objectives, operational responsiveness, and compatibility to avoid trading economies of scale for economies of integration. The final objectives of this paper are to share key ideas about the need to balance the growing customer service direct-to-consumer business models with those for collaborative investment by market and industry. In doing this, it hopes to promote an intelligent supply chain ecosystem foundation for helping its different participating countries survive and thrive in the digital economy.